Literature DB >> 19713064

Improved visualization of delayed perfusion in lung MRI.

Frank Risse1, Monika Eichinger, Hans-Ulrich Kauczor, Wolfhard Semmler, Michael Puderbach.   

Abstract

INTRODUCTION: The investigation of pulmonary perfusion by three-dimensional (3D) dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was proposed recently. Subtraction images are generated for clinical evaluation, but temporal information is lost and perfusion defects might therefore be masked in this process. The aim of this study is to demonstrate a simple analysis strategy and classification for 3D-DCE-MRI perfusion datasets in the lung without omitting the temporal information.
MATERIALS AND METHODS: Pulmonary perfusion measurements were performed in patients with different lung diseases using a 1.5 T MR-scanner with a time-resolved 3D-GRE pulse sequence. 25 3D-volumes were acquired after iv-injection of 0.1 mmol/kg KG Gadolinium-DTPA. Three parameters were determined for each pixel: (1) peak enhancement S(n,max) normalized to the arterial input function to detect regions of reduced perfusion; (2) time between arterial peak enhancement in the large pulmonary artery and tissue peak enhancement τ to visualize regions with delayed bolus onset; and (3) ratio R=S(n,max)/τ was calculated to visualize impaired perfusion, irrespectively of whether related to reduced or delayed perfusion.
RESULTS: A manual selection of peak perfusion images is not required. Five different types of perfusion can be found: (1) normal perfusion; (2) delayed non-reduced perfusion; (3) reduced non-delayed perfusion; (4) reduced and delayed perfusion; and (5) no perfusion. Types II and IV could not be seen in subtraction images since the temporal information is necessary for this purpose.
CONCLUSIONS: The analysis strategy in this study allows for a simple and observer-independent visualization and classification of impaired perfusion in dynamic contrast-enhanced pulmonary perfusion MRI by using the temporal information of the datasets.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713064     DOI: 10.1016/j.ejrad.2009.07.025

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

Review 1.  [MRI methods for pulmonary ventilation and perfusion imaging].

Authors:  G Sommer; G Bauman
Journal:  Radiologe       Date:  2016-02       Impact factor: 0.635

Review 2.  Ten years of chest MRI for patients with cystic fibrosis : Translation from the bench to clinical routine.

Authors:  Patricia Leutz-Schmidt; Monika Eichinger; Mirjam Stahl; Olaf Sommerburg; Jürgen Biederer; Hans-Ulrich Kauczor; Michael U Puderbach; Marcus A Mall; Mark O Wielpütz
Journal:  Radiologe       Date:  2019-12       Impact factor: 0.635

Review 3.  The role of advanced imaging techniques in cystic fibrosis follow-up: is there a place for MRI?

Authors:  Michael Puderbach; Monika Eichinger
Journal:  Pediatr Radiol       Date:  2010-04-30

4.  MRI of the lung (3/3)-current applications and future perspectives.

Authors:  Jürgen Biederer; S Mirsadraee; M Beer; F Molinari; C Hintze; G Bauman; M Both; E J R Van Beek; J Wild; M Puderbach
Journal:  Insights Imaging       Date:  2012-01-15

5.  Ventilation and perfusion magnetic resonance imaging of the lung.

Authors:  Grzegorz Bauman; Monika Eichinger
Journal:  Pol J Radiol       Date:  2012-01

6.  Dynamic susceptibility contrast 19 F-MRI of inhaled perfluoropropane: a novel approach to combined pulmonary ventilation and perfusion imaging.

Authors:  Mary A Neal; Benjamin J Pippard; A John Simpson; Peter E Thelwall
Journal:  Magn Reson Med       Date:  2019-08-29       Impact factor: 4.668

7.  Lung perfusion disturbances in nonhospitalized post-COVID with dyspnea-A magnetic resonance imaging feasibility study.

Authors:  Jimmy Z Yu; Tobias Granberg; Roya Shams; Sven Petersson; Magnus Sköld; Sven Nyrén; Johan Lundberg
Journal:  J Intern Med       Date:  2022-08-10       Impact factor: 13.068

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.